Colinz Laboratories Quarterly Results for Trading Insights
In March 2026, Colinz Laboratories (COLINZ) reported revenue ₹6 Cr and net profit ₹1 Cr — revenue -14.3% YoY. Also explore COLINZ stock price history to track price trends across different timeframes.
COLINZ Quarterly Results — Revenue, Profit & EPS Highlights
Colinz Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit COLINZ share price screener.
- Revenue of ₹6 Cr in March 2026 (-14.3% vs March 2025, -14.3% vs March 2025)
- Net Profit of ₹1 Cr in March 2026 (+0.0% vs March 2025, +0.0% vs March 2025)
- Operating Margin of 7.0% in March 2026 (-1.0pp vs March 2025)
- Earnings Per Share of ₹2.04 in March 2026 (+3.6% vs March 2025)
Colinz Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
COLINZ quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 6 | 7 | 7 | 7 | 7 | -14.3% | -14.3% |
| Net Profit (₹ Cr) | 1 | 1 | 1 | 1 | 0 | - | - |
| EBITDA (₹ Cr) | 0 | 1 | 1 | 1 | 1 | - | - |
| EPS (₹) | 2.04 | 1.97 | 1.93 | 1.82 | 0.74 | - | - |
| Operating Margin (%) | 7.0% | 8.0% | 8.0% | 9.0% | 8.0% | - | - |
COLINZ Share Price Trend — 1-Year Movement Across Quarterly Results
Colinz Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with Colinz Laboratories valuation methods to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
COLINZ vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Colinz Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1844.6 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 163.2 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6887.0 | 2,860 | 689 | +7.1% | - | 24.1% | 265.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹151,833.39 Cr | 4486.2 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 389.8 |
|
Cipla
Mar 2026 |
₹113,024.67 Cr | 1399.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 203.7 |
|
Dr Reddys Laborator…
Mar 2026 |
₹109,104.54 Cr | 1307.2 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 493.3 |
All amounts in ₹ Crores